Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
Galectin Therapeutics Presents 3 Abstracts At The American Association For The Study Of Liver Diseases 2024 Liver Meeting
galectin therapeutics在2024年美國肝病研究協會肝臟會議上發佈了3篇摘要
- Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosis
- Blinded central review system can be effectively set-up for evaluation of esophagogastoduodenoscopy (EGD) in large multi-center trial of patients with MASH cirrhosis and portal hypertension, facilitating utilization of this outcome as a critical endpoint in portal hypertension trials
- Approximately a third of patients with MASH cirrhosis and portal hypertension (PH) screened for the NAVIGATE trial had the incidental finding of varices on EGD, highlighting the need for screening EGDs in these patients
- NAVIGATE trial readout on track for December 2024
- NAVIGATE試驗的患者群體基於非侵入性測試和臨床標準，使用最新的MASH肝硬化門靜脈高壓治療指南
- 在針對MASH肝硬化和門靜脈高壓患者的大型多中心試驗中，可以有效地設置盲目中央審查系統來評估食管胃十二指腸鏡檢查（EGD），從而促進將該結果用作門靜脈高壓試驗的關鍵終點
- 在接受NAVIGE試驗篩查的MASH肝硬化和門靜脈高壓（PH）患者中，約有三分之一偶然發現EGD上有靜脈曲張，這凸顯了對這些患者進行EGD篩查的必要性
- NAVIGATE 試用版有望在 2024 年 12 月發佈
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.
喬治亞州諾克羅斯，2024年11月18日（GLOBE NEWSWIRE）——靶向半乳糖凝集素蛋白療法的領先開發商Galectin Therapeutics, Inc.（納斯達克股票代碼：GALT）今天在11月舉行的美國肝病研究協會（AASLD）2024年肝臟會議上發佈了三張海報，介紹正在進行的針對MASH肝硬化和門靜脈高壓患者的NAVIGE試驗 2024 年 15 月 19 日在加利福尼亞州聖地亞哥舉行。
資訊熱榜
更新時間